Nautilus Biotechnology, Inc. (NAUT) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Nautilus Biotechnology, Inc. (NAUT) trades at $0.9023 with AI Score 15/100 (Grade F). Nautilus Biotechnology, Inc. is a development stage life sciences company focused on quantifying and unlocking the complexity of the proteome. Market cap: $115M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: May 10, 2026Analyst Coverage for NAUT: NAUT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NAUT against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
NAUT: 2/3 scored disciplines lean bearish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Nautilus Biotechnology, Inc. (NAUT) Healthcare & Pipeline Overview
Nautilus Biotechnology, Inc. is a development-stage proteomics company creating a platform to analyze and quantify the proteome. The company's Nautilus Platform, encompassing instruments, consumables, and software, aims to provide comprehensive solutions for proteomics research. Nautilus is positioned to capitalize on the growing demand for advanced proteomic analysis tools.
What Is the Investment Thesis for NAUT?
Nautilus Biotechnology presents a compelling, albeit high-risk, investment opportunity within the proteomics space. The company's Nautilus Platform holds the potential to disrupt traditional proteomics methods by offering increased sensitivity and throughput. Key value drivers include successful commercialization of the Nautilus Platform, expansion of its applications across various research areas, and strategic partnerships with pharmaceutical companies. Upcoming catalysts include the launch of the Nautilus Platform and validation of its performance through peer-reviewed publications. Potential risks include delays in product development, competition from established proteomics companies, and the need for significant capital investment to scale up manufacturing and commercial operations. With a market capitalization of $115M, Nautilus is positioned for growth if it can successfully execute its commercialization strategy.
Based on FMP financials and quantitative analysis
NAUT Key Highlights
Nautilus Biotechnology is a development stage company focused on proteomics.
- The company is developing the Nautilus Platform, an end-to-end solution for proteomics research.
- Nautilus aims to quantify and unlock the complexity of the proteome.
- The company was founded in 2016 and is headquartered in Seattle, Washington.
- Nautilus Biotechnology has 134 employees.
Who Are NAUT's Competitors?
NAUT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
| MDXG MiMedx Group, Inc. | $4.45 | +2.53% | $649M | 90 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NAUT's Key Strengths?
Proprietary Nautilus Platform technology.
- End-to-end proteomics solution.
- Potential for high sensitivity and throughput.
- Experienced leadership team.
What Are NAUT's Weaknesses?
Development stage company with no current revenue.
- Reliance on successful commercialization of the Nautilus Platform.
- High capital requirements for manufacturing and commercial operations.
- Limited market presence.
What Could Drive NAUT Stock Higher?
Launch of the Nautilus Platform.
- Validation of the platform's performance through peer-reviewed publications.
- Strategic partnerships with pharmaceutical and research institutions.
What Are the Key Risks for NAUT?
Financial-distress signal — its Altman Z-Score of -1.59 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-35.0%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Delays in product development.
- Competition from established proteomics companies.
- Regulatory hurdles for diagnostic assays.
- High capital requirements for manufacturing and commercial operations.
What Are the Growth Opportunities for NAUT?
- Expansion into Drug Discovery: Nautilus can leverage its proteomics platform to offer services to pharmaceutical companies for drug target identification and validation. The global drug discovery market is projected to reach $85 billion by 2028, presenting a significant opportunity for Nautilus to generate revenue through research collaborations and service agreements. This expansion would involve partnering with pharmaceutical firms to utilize the Nautilus Platform in their drug development pipelines, potentially leading to milestone payments and royalty streams.
- Development of Diagnostic Assays: Nautilus can develop diagnostic assays based on its proteomics platform for early disease detection and personalized medicine. The in vitro diagnostics market is expected to reach $100 billion by 2027, driven by the increasing demand for accurate and timely diagnostic information. Nautilus could partner with diagnostic companies or develop its own line of diagnostic products, focusing on areas such as cancer, cardiovascular disease, and infectious diseases. This would require regulatory approvals and clinical validation of the assays.
- Strategic Partnerships with Research Institutions: Collaborating with leading research institutions to validate and showcase the capabilities of the Nautilus Platform can drive adoption and generate publications. These partnerships can provide access to valuable research data and expertise, as well as opportunities to co-develop new applications for the platform. By establishing strong relationships with key opinion leaders in the proteomics field, Nautilus can enhance its credibility and accelerate commercialization.
- Expansion into New Geographic Markets: Nautilus can expand its commercial operations into new geographic markets, such as Europe and Asia, to capitalize on the growing demand for proteomics solutions worldwide. This expansion would involve establishing sales and marketing teams in these regions, as well as adapting the Nautilus Platform to meet local regulatory requirements. The global proteomics market is expected to grow significantly in the coming years, driven by increasing investments in research and development in emerging economies.
- Development of Software and Data Analysis Tools: Nautilus can develop advanced software and data analysis tools to complement its proteomics platform and provide researchers with comprehensive insights into their data. This would involve creating user-friendly interfaces and algorithms for data visualization, statistical analysis, and machine learning. By offering a complete solution that includes both hardware and software, Nautilus can differentiate itself from competitors and attract a wider range of customers. The market for bioinformatics software is expected to grow as researchers increasingly rely on computational tools to analyze complex biological data.
What Are NAUT's Competitive Advantages?
- Proprietary Nautilus Platform technology.
- End-to-end solution encompassing instruments, consumables, and software.
- Potential for high sensitivity and throughput in protein analysis.
- Strategic partnerships with leading research institutions.
What Does NAUT Do?
Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology, Inc. is a life sciences company focused on revolutionizing the field of proteomics. Recognizing the limitations of existing technologies in fully understanding the complexity of the proteome, Nautilus embarked on developing its proprietary Nautilus Platform. This platform is designed as an end-to-end solution, integrating instruments, consumables, and software analysis to enable researchers to quantify and analyze proteins at an unprecedented scale and with high sensitivity. The Nautilus Platform aims to accelerate drug discovery, diagnostics development, and personalized medicine by providing deeper insights into protein function and interactions. As a development stage company, Nautilus is currently focused on refining its platform and preparing for commercial launch. The company's strategy involves establishing partnerships with leading research institutions and pharmaceutical companies to validate its technology and drive adoption. Nautilus believes its platform will transform proteomics research and unlock new possibilities in understanding and treating diseases.
What Products and Services Does NAUT Offer?
- Develops the Nautilus Platform, a proteomics platform.
- Creates instruments for protein analysis.
- Produces consumables used in the proteomics process.
- Provides software for analyzing proteomics data.
- Aims to quantify and unlock the complexity of the proteome.
- Offers an end-to-end solution for proteomics research.
- Focuses on accelerating drug discovery and diagnostics development.
How Does NAUT Make Money?
- Develops and sells proteomics instruments.
- Sells consumables required for the Nautilus Platform.
- Generates revenue through software licenses and data analysis services.
- Forms strategic partnerships with pharmaceutical and research institutions.
What Industry Does NAUT Operate In?
The proteomics market is experiencing rapid growth, driven by the increasing demand for personalized medicine and the need for better understanding of disease mechanisms. Companies like Nautilus Biotechnology are positioned to capitalize on this trend by developing innovative technologies that enable more comprehensive and accurate protein analysis. The competitive landscape includes established players in the life sciences industry, as well as emerging companies focused on novel proteomics approaches. The market is expected to continue to grow as researchers and clinicians increasingly rely on proteomics data to advance drug discovery and improve patient outcomes.
Who Are NAUT's Key Customers?
- Pharmaceutical companies involved in drug discovery.
- Biotechnology companies focused on proteomics research.
- Academic research institutions studying protein function.
- Diagnostic companies developing new assays.
Company Profile
Nautilus Biotechnology, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Seattle, US. The company is led by CEO Sujal Patel. NAUT has traded publicly since 2020.
How Nautilus Biotechnology, Inc. Is Valued
Nautilus Biotechnology, Inc. carries a market capitalization of $115M, placing it in the micro-cap category. Relative to its peer group, NAUT's quantitative score of 15/100 is below the peer average of 76/100.
Key Financial Metrics
Return on equity for Nautilus Biotechnology, Inc. stands at -35.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -32.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -20.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 11.85 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -23.3%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Nautilus Biotechnology, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -1.59 places it in the distress zone, a signal of elevated financial risk.
Earnings Track Record
Nautilus Biotechnology, Inc. has beaten Wall Street's EPS estimate in 8 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 18.7% above estimates on average.
Forward Outlook
Wall Street analysts project Nautilus Biotechnology, Inc. revenue of about $500K for fiscal 2026, with EPS near $-0.51.
NAUT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- NAUT's recent insider buying suggests those in the know see long-term value, signaling potential confidence in the company's future prospects. Think of it like when insiders loaded up on Tesla before its 2020 surge.
- The social trading community is buzzing with positive sentiment around NAUT's innovative technology, creating a groundswell of support. This mirrors the early enthusiasm for CRISPR gene editing companies.
- NAUT's focus on proteomics and drug discovery positions it in a high-growth sector, attracting investors looking for the next big breakthrough. It's similar to the early days of genomics companies.
- Despite market volatility, NAUT has maintained a relatively stable community following, indicating sustained interest and potential for future growth. This is a positive sign compared to companies with fleeting hype.
Bear Case
- Recent market perception casts doubt on NAUT's ability to rapidly commercialize its technology, leading to investor skepticism. This is similar to the challenges faced by early-stage biotech firms.
- The social trading community expresses concerns about NAUT's cash burn rate and potential need for future funding rounds, creating uncertainty. This echoes worries about companies during the dot-com bubble.
- Bearish community views highlight the competitive landscape and potential challenges to NAUT's market share, suggesting a difficult path ahead. This is reminiscent of the intense competition in the electric vehicle market.
- Despite positive sentiment in some circles, there's a segment of the community questioning NAUT's long-term viability, citing concerns about regulatory hurdles. These concerns are like those surrounding new medical device approvals.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $190,000 | -$14M | -$0.11 |
Based on FMP financials and quantitative analysis
NAUT Latest News
-
Amazon Sold Holding In Nautilus Biotechnology
benzinga · Aug 6, 2026
-
12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga · Jul 28, 2026
NAUT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NAUT.
Price Targets
Wall Street price target analysis for NAUT.
NAUT MoonshotScore
What does this score mean?
The MoonshotScore rates NAUT 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Sujal Patel
CEO
Sujal Patel is the CEO of Nautilus Biotechnology, Inc. He has a background in technology and entrepreneurship, with experience in building and scaling innovative companies. Prior to Nautilus, Sujal was involved in various ventures in the technology sector. His expertise includes product development, business strategy, and team leadership. He brings a wealth of experience to Nautilus, guiding the company's vision and execution.
Track Record: Under Sujal Patel's leadership, Nautilus Biotechnology has focused on developing the Nautilus Platform and building strategic partnerships. Key milestones include advancing the platform's technology, securing funding, and expanding the team. Sujal's strategic decisions have positioned Nautilus for growth in the proteomics market.
Common Questions About NAUT (Healthcare)
What does the AI Score mean for NAUT?
NAUT holds an AI Score of 15/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. Nautilus Biotechnology, Inc. is a development stage life sciences company focused on quantifying and unlocking the complexity of the proteome. Their Nautilus Platform aims to provide an end-to-end …
What does Nautilus Biotechnology, Inc. do?
Nautilus Biotechnology, Inc. is a development stage life sciences company focused on creating a platform technology for quantifying and unlocking the complexity of the proteome. The company is developing the Nautilus Platform, an end-to-end proteomics solution comprised of instruments, consumables, and software analysis.
What do analysts say about NAUT stock?
As a development stage company, analyst coverage of Nautilus Biotechnology, Inc. (NAUT) is still emerging. Key valuation metrics will depend on the successful commercialization of the Nautilus Platform and its adoption by pharmaceutical and research institutions. Growth considerations include the company's ability to secure partnerships, expand its product offerings, and penetrate new markets. Investors should closely monitor the company's progress in achieving its milestones and managing its capital resources.
What are the main risks for NAUT?
The main risks for Nautilus Biotechnology, Inc. include the successful development and commercialization of the Nautilus Platform, competition from established proteomics companies, and the need for significant capital investment. Delays in product development, regulatory hurdles for diagnostic assays, and technological obsolescence also pose potential risks. Investors should carefully assess these risks before investing in NAUT.
What are the key factors to evaluate for NAUT?
Nautilus Biotechnology, Inc. (NAUT) holds an AI score of 15/100 (low). Nautilus Biotechnology presents a compelling, albeit high-risk, investment opportunity within the proteomics space. Not financial advice.
How frequently does NAUT data refresh on this page?
NAUT's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven NAUT's recent stock price performance?
Nautilus Biotechnology, Inc. (NAUT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary Nautilus Platform technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NAUT overvalued or undervalued right now?
Nautilus Biotechnology, Inc. (NAUT) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research NAUT before investing?
Before investing in Nautilus Biotechnology, Inc. (NAUT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- Nautilus Biotechnology, Inc. is a development stage company, and its future performance is uncertain.